<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03520920</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-3111-213</org_study_id>
    <nct_id>NCT03520920</nct_id>
  </id_info>
  <brief_title>BTK Inhibitor BGB-3111 in Chinese Patients With Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)</brief_title>
  <official_title>A Phase 2 Study to Assess the Safety, Tolerability, and Activity of BGB-3111 in Combination With Rituximab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Non-GCB Subtype) and Relapsed/Refractory Indolent Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Screening (up to 28 days); BGB-3111160 mg twice daily in combination with rituximab until
      disease progression, discontinued treatment due to intolerance, died, withdrew from study, or
      completed study treatment for a total of 2 years, treatment (up to 2 years), safety follow up
      (30 days); survival follow-up until patient death or study termination by the Sponsor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter open-label phase 2 study to evaluate efficacy, safety and tolerability
      of BGB-3111 160 mg twice daily in combination with rituximab in Chinese Patients with
      Relapsed/Refractory Diffuse Large B-Cell Lymphoma (non-GCB Subtype) and Relapsed/Refractory
      Indolent Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma）.

      The study is composed of two cohorts. Cohort 1 will be approximately 20 subjects and Cohort 2
      will be approximately 20 subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate（ORR）</measure>
    <time_frame>up to 2 years</time_frame>
    <description>The achievement of either a partial response (PR) or complete response (CR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Defined as time from first dose of BGB-3111 until first documentation of Progression (by IWG on NHL criteria) or death, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Defined as the time from the date that the response criteria are first met to the date that progressive disease (PD) is objectively documented or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Defined as the time from first dose of BGB-3111 until death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response (TTR)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Defined as the time from first dose of BGB-3111 to documentation of a response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complete response or complete metabolic response</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Defined as the time from first dose of BGB-3111 to complete response or complete metabolic response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Marginal Zone Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <condition>Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>cohort 1 and cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BGB-3111 in combination with Rituximab in relapsed/refractory non-GCB DLBCL and relapsed/refractory follicular (FL) or marginal zone lymphoma (MZL)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-3111</intervention_name>
    <description>BGB-3111 at a dose of 160 mg orally (PO) twice daily (BID)
Rituximab will be administered at 375 mg/m2 intravenously on Cycle 1 Days 1, 8, 15, 22, and on Day 1 of Cycles 4, 6, 8, 10.</description>
    <arm_group_label>cohort 1 and cohort 2</arm_group_label>
    <other_name>Rituximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age ≥ 18 years at time of signing of informed consent.

          -  2. Measurable disease by CT or positron emission tomography (PET)/CT or magnetic
             resonance imaging (MRI), defined as ≥ 1 nodal lesion that is &gt; 1.5 cm in the longest
             diameter, or ≥ 1 extra-nodal lesion (e.g. hepatic nodules) that is &gt; 1 cm in the
             longest diameter.

          -  3. Availability of archival or fresh tumor tissue sample from an evaluable core or
             excisional biopsy.

          -  4. Patients meet the following criteria:

               1. Cohort 1: R/R non-GCB DLBCL I. Histologically confirmed non-GCB DLBCL per Hans
                  criteria with non-transformed disease ii. Relapsed disease (disease progression
                  after most recent therapy for DLBCL) or refractory disease (failure to achieve CR
                  or PR to therapy for non-GCB DLBCL or disease progression within 6 months after
                  completion of the most recent therapy for non-GCB DLBCL) iii. Must have received
                  at least one standard anthracycline ± rituximab based treatment (e.g. R- CHOP) or
                  CVP+/- R for DLBCL

               2. Cohort 2: R/R FL or R/R MZL I. Histologically confirmed CD20+ FL (Grade 1, 2, or
                  3a) or MZL ii. Relapsed disease (disease progression after most recent therapy
                  for FL or MZL occurring more than 6 months after the completion of last therapy)
                  or refractory disease (failure to achieve CR or PR to most recent therapy for FL
                  or MZL, or disease progression within 6 months after completion of the most
                  recent therapy for FL or MZL).

          -  5. Laboratory parameters as specified below:

               1. Hematologic: Platelet count ≥ 75 x 109/L independent of growth factor or
                  transfusion within 7 days of study entry; ANC ≥ 1 x 109/L independent of growth
                  factor within 7 days of study entry, hemoglobin (Hgb) &gt; 8 g/dL within 7 days of
                  study entry.

               2. Hepatic: Total bilirubin ≤ 2x upper limit of normal (ULN) unless documented
                  Gilbert's syndrome; aspartate aminotransferase (AST)/serum glutamic-oxaloacetic
                  transaminase (SGOT) and alanine transaminase (ALT)/serum glutamic-pyruvic
                  transaminase (SGPT) ≤ 3x ULN.

               3. Renal: Creatinine clearance ≥ 30 mL/min (as estimated by the Cockcroft-Gault
                  equation based on ideal body weight or as measured by nuclear medicine scan or 24
                  hour urine collection)

               4. International normalized ratio and aPTT ≤ 1.5x ULN. Patients with
                  anti-phospholipid syndrome, acquired von Willebrand disease, factor inhibitors or
                  on vitamin K antagonist may be enrolled after discussion with the Medical
                  Monitor.

          -  6. LVEF ≥ 50%.

          -  7. Life expectancy ≥ 6 months.

          -  8. Eastern Cooperative Oncology Group performance status of 0, 1, or 2.

          -  9. Female patients of childbearing potential must practice highly effective methods of
             contraception initiated prior to first dose of study drug, for the duration of the
             study, and for ≥ 90 days after the last dose of BGB-3111, or 12 months after the last
             dose of rituximab, whichever is longer.

          -  10.Male patients are eligible if vasectomized or if they agree to the use of barrier
             contraception in combination with other methods above during the study treatment
             period and for ≥ 90 days after the last dose of BGB-3111.

          -  11.Able to provide written informed consent and can understand and comply with the
             requirements of the study.

        Exclusion Criteria:

          -  1. Known central nervous system lymphoma or leukemia.

          -  2. Histological confirmed gastric MALT type MZL.

          -  3. Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura.

          -  4. Clinically significant cardiovascular disease.

          -  5. History of severe bleeding disorder such as hemophilia A, hemophilia B, von
             Willebrand disease, or history of spontaneous bleeding requiring blood transfusion or
             other medical intervention

          -  6. History of stroke or intracranial hemorrhage within 6 months before first dose of
             study drug.

          -  7. Severe or debilitating pulmonary disease.

          -  8. Hypersensitivity reaction to BGB-3111 or rituximab or any of the other ingredients
             of the study drugs.

          -  9. Prior BTK inhibitor treatment.

          -  10. Requires ongoing treatment with a strong CYP3A inhibitor or inducer.

          -  11. Vaccination with a live vaccine within 28 days of the first dose of study drug.

          -  12. Hematopoietic stem cell transplantation within 6 months of first dose of study
             drug.

          -  13. Receipt of the following treatment prior to first dose of study drug:

               1. Corticosteroids at doses &gt;20 mg/day prednisone equivalent or steroids given with
                  anti-neoplastic intent within 7 days prior to first dose of study drug.

               2. Chemotherapy or radiotherapy within 4 weeks.

               3. Monoclonal antibody within 4 weeks.

               4. Investigational therapy within 4 weeks.

               5. Chinese patent medicine with anti-neoplastic intent within 4 weeks.

          -  14. Not recovered from toxicity of any prior anti-cancer therapy to ≤ Grade 1, except
             for alopecia, ANC, Hgb and platelets. For ANC, Hgb and platelets, see inclusion
             criterion #5.

          -  15. Prior malignancy within the past 3 years, except for curatively treated basal or
             squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the
             cervix or breast.

          -  16. Unable to swallow capsules or disease significantly affecting gastrointestinal
             function such as malabsorption syndrome, resection of the stomach or small bowel,
             symptomatic inflammatory bowel disease, history of bariatric surgery, or partial or
             complete bowel obstruction.

          -  17. Major surgery within 4 weeks prior to first dose of study treatment.

          -  18. Active fungal, bacterial and/or viral infection requiring systemic therapy.

          -  19. Known infection with human immunodeficiency virus (HIV), or serologic status
             reflecting active hepatitis B or C infection as follows:

               1. Presence of hepatitis B surface antigen (HBsAg) or anti-hepatitis B core antibody
                  (anti-HBc). Patients with presence of anti-HBc, but absence of HBsAg, are
                  eligible if hepatitis B virus (HBV) DNA is &lt; 500 IU/mL, anti-viral therapy
                  started before the first dose of study treatment, and if they are willing to
                  undergo monthly monitoring for HBV reactivation.

               2. Presence of hepatitis C virus (HCV) antibody. Patients with presence of HCV
                  antibody are eligible if HCV RNA is undetectable (&lt;15 IU/mL).

          -  20. Pregnant or lactating women.

          -  21. Underlying medical conditions that, in the investigator's opinion, will render the
             administration of study drug hazardous or obscure the interpretation of toxicity or
             AEs.

          -  22. Concurrent participation in another therapeutic clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Meng Ji</last_name>
    <phone>+86 4008203159</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingyuan Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ongji Hospital, Tongji Medical College of HUST</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianfeng Zhou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenyu Li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Mdicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rong Tao</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2018</study_first_submitted>
  <study_first_submitted_qc>April 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2018</study_first_posted>
  <last_update_submitted>April 28, 2018</last_update_submitted>
  <last_update_submitted_qc>April 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

